Immatics Reports Promising Early Results for IMA203CD8 PRAME Cell Therapy in Phase 1a Trial
I'm PortAI, I can summarize articles.
Immatics N.V. announced promising early results from its Phase 1a trial of IMA203CD8, a PRAME-targeting cell therapy, in patients with solid tumors. The interim data, presented at the ESMO Immuno-Oncology Congress 2025, showed manageable tolerability and encouraging anti-tumor activity. The trial aims to complete dose escalation and determine the recommended Phase 2 dose by 2026. The news was originally published by Immatics NV via GlobeNewswire on December 11, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments